Effects of the triple therapy of carnosine glycoside, edaravone, and Xueshuantong in hemorrhagic cerebral infarction

Lili Shang; Xiuzhen Wang; Hong Sun; Wei Wei; Yuanzheng Sun; Guofeng Cai; Minna Jiao; Shiwei Zhang; Shiwei Li; Shengnan Xu; Aijun Quan

Effects of the triple therapy of carnosine glycoside, edaravone, and Xueshuantong in hemorrhagic cerebral infarction

Am J Transl Res. 2022 Feb 15;14(2):1024-1033. eCollection 2022.

Authors

Lili Shang¹, Xiuzhen Wang², Hong Sun¹, Wei Wei³, Yuanzheng Sun⁴, Guofeng Cai², Minna Jiao¹, Shiwei Zhang¹, Shiwei Li⁴, Shengnan Xu⁴, Aijun Quan¹

Affiliations

¹ Department of Intensive Medicine Harbin 150001, Heilongjiang, China.
² Internal Medicine Ward I Harbin 150001, Heilongjiang, China.
³ Department of Radiology Harbin 150001, Heilongjiang, China.
⁴ Department of Acupuncture, The Second Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine Harbin 150001, Heilongjiang, China.

PMID: 35273704
PMCID: PMC8902570

Abstract

Objective: This study was designed to evaluate the effects of the triple therapy of Muscular Amino Acid and Peptides and Nucleosides (MAAPN), edaravone, and Xueshuantong on neurological function, tumor volume, and adverse reactions in patients with hemorrhagic cerebral infarction.

Methods: In this retrospective study, a total of 115 patients with hemorrhagic cerebral infarction admitted to the hospital from January 2020 to January 2021 were enrolled and assigned to the observation group (n=57) or the control group (n=58) according to different treatment methods. The two groups were both treated with a conventional treatment regimen, and the observation group was additionally given carnosine, edaravone, and Xueshuantong, with a course of treatment spanning 14 days. The neurological and motor functions and changes in cerebral edema and cerebral infarct lesion size in patients were evaluated. The levels of inflammatory factors, blood lipids, neuron-specific enolase (NSE), S-100β, and matrix metalloproteinase-9 (MMP-9) of the two groups were determined and compared. The adverse effects and rebleeding of patients were recorded. The Barthel index (BI) was used to evaluate the quality of life of patients.

Results: The treatment efficiency in the observation group was significantly higher than that in the control group (P<0.05). After treatment, the observation group obtained more favorable outcomes in terms of the neurological and motor functions, lesions of brain edema and cerebral infarction, and BI scores, than those of the control group (all P<0.05). In addition, after treatment, the levels of inflammatory factors, blood lipids, NSE, S-100β, MMP-9, plasma viscosity, and whole blood viscosity of the two groups of patients all decreased remarkably, with better outcomes in the observation group when compared with the control group (all P<0.05). The observation group showed a markedly lower rebleeding rate than the control group (P<0.05).

Conclusion: For patients with hemorrhagic cerebral infarction, the triple therapy of carnosine glycoside, edaravone, and Xueshuantong effectively enhances the neurological and motor function, reduces cerebral edema and cerebral infarction, and improves the quality of life, with high safety.

Keywords: Hemorrhagic cerebral infarction; Xueshuantong; adverse effect; edaravone; muscular amino acid and peptides and nucleosides; neurological function; triple therapy; tumor volume.